Form 4 for LCTX Lineage Cell Therapeutics, Inc.
Accepted 2022-01-03 00:00:00 ET · period of report 2021-12-31 · accession 0001493152-22-000116 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-01-03 | 2021-12-31 | LCTX | Culley Brian M | Pres, CEO, Dir | M - OptEx | — | +15.4K | 81.4K | +23% | — |
| D | 2022-01-03 | 2021-12-31 | LCTX | Culley Brian M | Pres, CEO, Dir | F - Tax | $2.45 | -5,343 | 76.0K | -7% | -$13.1K |
| D | 2022-01-03 | 2021-12-31 | LCTX | Culley Brian M | Pres, CEO, Dir | M - OptEx | $0.00 | -15.4K | 30.9K | -33% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Shares, no par value | 2021-12-31 | M | A | 15,450 | — | 81,373 | D | — | — | (F1) Shares earned by the reporting person as a result of the vesting of a portion of restricted stock units ("RSUs") granted to the reporting person on September 17, 2018. Upon settlement, RSUs convert into common shares of the issuer on a one-for-one basis. (F2) Does not include common shares of the issuer that may be acquired upon settlement of RSUs that have not vested as of the date of this filing or upon the exercise of stock options outstanding as of the date of this filing. |
| 2 | Common | Common Shares, no par value | 2021-12-31 | F | D | 5,343 | $2.45 | 76,030 | D | — | — | (F3) Shares withheld by the issuer to satisfy statutory tax withholding requirements on the vesting of 15,450 RSUs in a transaction exempt under Rule 16(b)-3. No shares were sold in connection with this transaction. (F2) Does not include common shares of the issuer that may be acquired upon settlement of RSUs that have not vested as of the date of this filing or upon the exercise of stock options outstanding as of the date of this filing. |
| 3 | Derivative | Restricted Stock Units | 2021-12-31 | M | D | 15,450 | $0.00 | 30,900 | D | $0.00 · — to — | 15,450 Common Shares | (F4) The reporting person was granted RSUs on September 17, 2018, that vested with respect to 25% of the shares subject to the award on September 17, 2019, and the balance vest in 12 equal quarterly installments at the end of each quarter thereafter. |